ABSTRACT The binding of '5I-labeled mouse epidermal growth factor (EGF) to 18 cell lines, including HeLa (human carcinoma), MDCK (dog kidney cells), HTC (rat hepatoma), K22 (rat liver), HF (human foreskin), GM17 (human skin fibroblasts), XP (human xeroderma pigmentosum fibroblasts), and 3T3-LI (mouse fibroblasts), was inhibited by saccharin and cyclamate. The human cells were more sensitive to inhibition by these sweeteners than mouse or rat cells. EGF at doses far above the physiological levels reversed the inhibition in rodent cells but not in HeLa cells. In HeLa cells, the doses of saccharin and cyclamate needed for 50% inhibition were 3.5 and 9.3 mg/ml, respectively. Glucose, 2-deoxyglucose, sucrose, and xylitol did not inhibit EGF binding. Previous studies have shown that phorbol esters, strongly potent tumor promoters, also inhibit EGF binding to tissue culture cells. To explain the EGF binding inhibition by such greatly dissimilar molecules as phorbol esters, saccharin, and cyclamate, it is suggested that they operate through the activation of a hormone response control unit.
Cancer-inducing agents have been classified as initiators or promoters according to their effects on the carcinogenic process (1) (2) (3) (4) (5) . A tumor promoter is a substance which, when repeatedly applied to animals previously exposed to a tumor initiator, greatly enhances the production of tumors (1) (2) (3) (4) (5) . Extensive studies have revealed that initiators interact with cellular DNA, but the initial biological events in the action of tumor promoters are less-well understood (2, 3) . Current knowledge of tumor promotion is largely derived from studies of the biological effects exerted by the potent tumor promoter 12-0-tetradecanoylphorbol 13 -acetate (TPA) (1) (2) (3) (4) (5) . The effects exhibited by such promoters at hormone-like levels in cellular systems have been used to search for the receptor systems involved in tumor promotion (3, 6) . It recently was shown that phorbol esters inhibit the binding of epidermal growth factor (EGF) to cellular receptors and that their potencies in the inhibition of EGF binding correlate well with their effects as tumor promoters on mouse skin (6, 7) .
Mouse EGF is a peptide of molecular weight 6000 (8, 9) . It exhibits all the biological activities ascribed to human EGF and competes specifically for binding to human EGF receptors (10, 11) . It can stimulate proliferation of both ectodermal and mesodermal cells in culture, increase deoxyglucose transport, induce the enzyme ornithine decarboxylase, and stimulate prostaglandin synthesis (12) (13) (14) (15) . Rose et aL (16) have shown that EGF (2) (3) (4) (5) ,ug/g of body weight) can enhance skin tumor induction in mice. Many of the effects induced by EGF are also exerted by TPA (6, 7) . The reason for such parallelism in biological activity is not clear at this time. However, it has been shown that TPA can synergistically enhance the mitogenic effect of EGF (17, 18) and that TPA inhibition of EGF binding apparently is not due to a direct competition between TPA and EGF for the active site of either the EGF receptor or the TPA receptor (7) . Recent studies also revealed that EGF binding is accompanied by a host of dynamic changes in the cell membrane including patching, internalization, and down-regulation (19) (20) (21) (22) (23) . Although the specific physiological roles of EGF and EGF receptors are not well understood, it seems plausible that the regulation of EGF levels in the body and the regulation of EGF receptors in the cells could be important events in tumor promotion.
The carcinogenicity of saccharin and cyclamate has received considerable attention because of their widespread use as artificial sweeteners (24-29, *). Much work has been done on their mutagenicity in bacteria (30) (31) , their tumorigenicity in animals (24-28, t), and their epidemiological correlations with human cancers (32) (33) (34) (35) (36) (37) (38) . The reported effects of these artificial sweeteners are confusing and contradictory. It seems more likely that saccharin and cyclamate function as weakly potent tumor promoters rather than initiators when administered to animals at high doses (29, 39, 40) , although this remains to be confirmed. The molecular action of these two compounds is unknown. Identification of the molecular target in the cell may provide new insight in the elucidation of their tumor-promoting activity.
Accordingly, it seemed worthwhile to determine whether some of the effects exerted by TPA, such as the inhibition of EGF binding, might also be exerted by them. I report here that such an effect occurs within 1 hr of exposure of human, mouse, hamster, rat, and dog cells in culture to saccharin or cyclamate and that it is not due to the toxicity of these compounds at the levels used. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. in Dulbecco's phosphate-buffered saline. TPA stock solutions were prepared in dimethyl sulfoxide.
MATERIALS AND METHODS

Materials
Cell Culture. The media used in culturing different cell lines were as follows: A, Eagle's minimal essential medium (ME medium) plus 5% fetal calf serum; B, ME medium plus 10% heat-inactivated fetal calf serum; C, ME medium plus 5% heatinactivated fetal calf serum; D, Dulbecco's modified ME medium plus 10% calf serum; E, F-12 medium plus 10% heat-inactivated fetal calf serum; F, Dulbecco's ME medium plus 10% fetal calf serum; G, Dulbecco's ME medium plus 10% heat-inactivated fetal calf serum; H, F-12medium plus 10% calf serum; and I, F-12 medium plus 10% fetal calf serum. All cultures were grown at 370C in humidified 5% C02/95% air. The cells were counted with a Coulter Counter (model Zb).
Human carcinoma HeLa cells were grown in medium D. HTG was a thioguanine-resistant mutant of HeLa. The K22 epithelial cell line was isolated from liver of normal young adult Lew/Mai rats (41) and was grown in medium E. The HTC cell line was originally isolated from Morris hepatoma 7288C induced in a BUF rat by an aromatic amine carcinogen and was grown in medium H.
The IAR27 and IAR20-PCI epithelial cell lines were derived from normal 10-week-old BD VI rats (42) and provided by R. Montesano. At 24 weeks in culture, they did not form tumors but at 60 weeks in culture they did. They were maintained in medium I. Abbreviations used: IARI, IAR20PCI-24 week, passage 14; IAR2, IAR20PCI-40 week, passage 21; IAR3, IAR27-24 week, passage 5; IAR4, IAR27-60 week, passage 5.
MDCK (dog kidney cells) were grown in medium G. HF (human foreskin fibroblasts) were grown in medium F; passage 11 was used. 3T3 (mouse fibroblasts) were grown in medium C; 3T3-BP was a line transformed from 3T3 by treatment with benzo[a]pyrene and was grown in medium A. GM17 was a human skin fibroblast line derived from a man with a translocation between chromosomes 15 and 18 and was grown in medium B. CHO (Chinese hamster ovary) cells were grown in medium F. XP cells were skin fibroblasts of human xeroderma pigmentosum; they were obtained from the American Type Culture Collection and were maintained in medium B [XPI, ATCC-CRL 1162 (WoMec), passage 30, sex M, age 27; XPII, ATCC-CRL 1233 (Jay Tim), passage 15, sex F, age 7] .
Binding Assay. The binding assay with l"I-labeled EGF (125I-EGF) was performed as described (7) . The binding buffer consisted of ME medium plus (per liter): 1 g of bovine serum albumin, 0.1 g of KCl, 0.1 g of KH2PO4, 4.0 g of NaCl, and 1.06 g of Na2HPO4-7H2O. The binding was carried out with a 55-min incubation at 37°C. Nonspecific binding was determined by measurement in the presence of unlabeled EGF (2 ,ug/ml) and this value was subtracted from the value obtained with the labeled ligand alone. All assays were performed twice and the values presented are means. Duplicates agreed within 10%.
Iodination of EGF. This was performed by using the chloramine-T method according to Carpenter and Cohen (10) with slight modifications. Briefly, 3 mCi (1 Ci = 3.7 x 1010 becquerels) of carrier-free Na'25I solution (17 Ci/mg) was adjusted to pH 7.5 and mixed with 0.1 ml of EGF in Dulbecco's phosphatebuffered saline 20 ,ug/ml. Then, 12.5 ,ug of chloramine-T in water was added; after 45 sec at room temperature, the reaction was stopped with 25 ,ug of sodium metabisulfite, 0.1 ml of KI (100 mg/ml) was added, and the reaction vial was washed three times with 0.1 ml of KI solution. The labeled EGF was then isolated with a Bio-Gel P-2 column. The elution buffer contained 0.1% bovine serum albumin in 3ulbecco's phosphatebuffered saline. Lot A had a specific activity of 13,000 cpm/ ng; lot B had a specific activity of 61,739 cpm/ng; lot C was obtained from Collaborative Research and had a specific activity of 55,000 cpm/ng.
RESULTS
The dose-response relationships for the inhibition of EGF binding by addition of saccharin and cyclamate 10 min before 125I-EGF are shown in Fig 1. The doses causing 50% inhibition were about 3.5 mg/ml for saccharin and 9.3 mg/ml for cyclamate, when 2 ng of 125I-EGF was used in binding to 3.65 x 10' HeLa cells. Saccharin inhibition of EGF binding was not due to impurities in the preparations because lot 1022 and purified saccharin [used in the Canadian studies (25) ] gave the same results in our assays. Inhibition was negligible when the dose of saccharin was less than 1 ,ug/ml or that of cyclamate was less than 10 pug/ml (Fig. 1 Insets) . Slight variation of this 50% inhibition dose may occur with different doses of EGF or cell numbers. Similar potencies of saccharin and cyclamate in EGFbinding inhibition were also observed in other human cell types tested. For instance, in GM17 the 50% inhibition doses were 4.6 and 10.3 mg/ml for saccharin and cyclamate, respectively; in XPII they were 7.6and 11.6 mg/ml, respectively. When the binding assay was done in the presence of unlabeled EGF at levels (200 ng/ml) far above the physiological level, together with either saccharin at 3 mg/ml or cyclamate at 10 mg/ml, this inhibition was still observed in HeLa cells (Fig. 2) . On the other hand, there may be species differences (see below). (Table 1) . Table 2 shows the effects of saccharin, cyclamate, and TPA on the growth and detachment of human cells HeLa and XPII. None of these compounds showed an effect on the adhesion of human cells when cultures were exposed to these agents for 1 hr under the assay conditions. In agreement with previous observations, TPA showed slight inhibition of the growth of HeLa cells (7) . On the other hand, growth inhibition was observed after 2 days of incubation when either saccharin or cyclamate at 1.7 mg/ml was included in the culture medium. I 100 ng/ml) at 370C for 60 min in 5% C02/95% humidified air and then washing them three times with 5 ml of cold binding buffer.
t For the growth test, 1.4 x 106 HeLa cells were plated 24 hr before the medium was replaced with the same growth medium plus the indicated reagents (saccharin, 3 mg/ml; cyclamate, 3 mg/ml; TPA, 100 ng/ml) and the cell numbers were determined 3 days later.
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Proc. NatL Acad. Sci. USA 78 (1981) 1045 and XPII, saccharin at 13.3 mg/ml was more potent than cyclamate at 13.3 mg/ml whereas in other species, such as IAR cells (rat) and 10T1/2 (mouse), the converse was true. At present, there is no definite answer to question a. Although it is more likely that saccharin and cyclamate are weak tumor promoters with very weak initiating activity (29, 39, 40) which may not conform to the strict criterion established with potent carcinogens, this has not been generally accepted (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) . On the other hand, at present there are not enough data to permit the unequivocal claim that the EGF binding assay can be used without conditions for the testing of the activity of all tumor promoters. To establish such an assay system would require testing of saccharin or cyclamate analogs whose carcinogenicities are established unequivocally, as well as the testing of all the known tumor initiators and promoters. Nevertheless, EGF binding is inhibited by tumor-promoting phorbol esters. Furthermore, EGF per se is tumor promoting at high doses. It is interesting to point out that the doses of saccharin or cyclamate required to demonstrate their tumorigenic activity are very high (0. 1 to 0.001 M in tissue culture or 5% in diet in animal tests) (26, 39) With the above hypothesis to answer question e, we can derive a reasonable theory to answer question f: namely, in cells that have been exposed to a tumor initiator, prolonged and excess activation of the hormone response control unit can also affect the permanent changes in gene expressions that are involved in tumor promotion. The classical observation that low doses of tumor initiators produce negligible numbers of tumors in the absence of exogenous tumor promoters (1) (2) (3) indicates that endogenous growth factors, such as EGF, do not have tumor-promoting activities at normal physiological levels even though tumor promotion has been reported at very high levels (16) . Thus, the degree of stimulation of the hormone response control unit required for tumor promotion may require that some threshold be exceeded.
Further studies are required to deduce the way the hormone response control unit responds to stimulation by various compounds in different systems under various conditions, which may shed more light on the tumor-promoting activity of saccharin or cyclamate.
